Skip to content

Biohaven

US · BHVN #2805 by market cap Listed 2017
12.39 -1.26 -9.23%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

Price chart

Pre-market 13.59 -0.44%
After-hours 12.51 +0.97%
Overnight 13.70 +0.37%
16.9510.0712.392026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on BHVN?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is +10.2% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 9.9% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days D → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 02:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability F

How much profit the business keeps from each dollar of sales and capital.

Return on equity -310.8% Better than 2%
Return on invested capital -185.5% Better than 1%
Momentum B+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -10.5% Better than 50%
6-month return 31.1% Better than 90%
12-month return (ex latest month) 43.2% Better than 80%
Distance below 52-week high 32.1% Better than 39%
Financial Health C

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 3.2x Better than 75%
Debt to assets 63.0% Better than 7%
Analyst View A-

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 72.7% Better than 50%
Upside to average target 130.6% Better than 88%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -10.35%
1M +4.91%
3M -8.22%
6M +40.00%
YTD +9.74%
1Y +28.66%
3Y -59.51%

Key statistics

Price & volume

Prev close
13.65
Open
13.26
Day range
12.31 - 13.75
Avg price
12.68
Volume
2.39M
Turnover
30.37M
Amplitude
10.55%
52-week range
8.03 - 18.24

Valuation

P/E
-1.81
P/E (TTM)
-3.29
P/B
-19.06
EPS
-6.86
Net profit
-1.04B
Net assets
-98.19M

Share structure

Market cap
1.87B
Float cap
1.44B
Shares out
151.06M
Float shares
116.57M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2017-05-04
52-week range 43% of range
8.03 18.24

32.1% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-20.40M net over the window

Short interest

Shares short
15.01M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Biohaven (BHVN)?

Biohaven last traded at 12.39. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Biohaven's market cap?

About 1.87B.

What is the P/E ratio of Biohaven?

The trailing twelve-month P/E is -3.29. The Valuation tab shows it against the stock's own five-year range.

Does Biohaven pay a dividend?

Biohaven does not currently pay a regular dividend.

Is Biohaven a buy according to analysts?

The consensus of 11 analysts is a Buy rating, with an average 12-month price target of 28.57, which implies 130.6% upside from the current price. This is not investment advice.

What is Biohaven's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Biohaven a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 20:01:17 · For reference only, not investment advice and not tailored to your situation.

Biohaven discussion 0 comments

Add a comment